Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0038002 (
splenomegaly
)
9,873
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Murine acquired immunodeficiency syndrome (MAIDS) was induced in C57BL/6 mice following infection with the LP-BM5 retrovirus complex. Infected mice developed
splenomegaly
, lymphadenopathy and loss of B- and T-cell functions 100 days after virus inoculation. Mice with AIDS were highly susceptible to opportunistic murine cytomegalovirus (MCMV) and herpes simplex virus (HSV-1) infections. The therapeutic activities of two phosphonylmethoxyalkyl derivatives, 9-(2-phosphonylmethoxyethyl)adenine (
PMEA
) and (S)-1-(3-hydroxy-2-phosphonylmethoxy-propyl)cytosine (HPMPC), were evaluated in MAIDS immunosuppressed mice infected with MCMV or HSV-1. MCMV infection resulted in extensive viral replication in lung, liver and spleen and death occurred five to twelve days post-infection. Treatment with either HPMPC or ganciclovir (DHPG) reduced mortality and viral replication in target organs; however, HPMPC was as effective as DHPG at one-fifth the DHPG dose. Moreover, when a single dose (100 mg/kg) of HPMPC was administered 24 h prior to MCMV infection, it suppressed virus replication at seven and 14 days post-infection, thus resulting in a significant prolongation of life.
PMEA
was effective against opportunistic HSV-1 infections, but appeared to be less effective than HPMPC against MCMV infections. These results indicate that MAIDS can be used as a model for evaluating antivirals in an immunocompromised host, and suggest that both
PMEA
and HPMPC may be useful in the treatment of opportunistic CMV and HSV-1 infections.
...
PMID:Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS. 166 26
Lipophilic ester prodrugs of 9-(2-phosphonylmethoxyethyl)adenine (
PMEA
), i.e., bis(pivaloyloxymethyl)-
PMEA
[bis(POM)-
PMEA
] and diphenyl-
PMEA
, have been synthesized in an attempt to increase the oral bioavailability of this broad-spectrum antiviral agent. The antiretroviral efficacy was determined in severe combined immune deficiency (SCID) mice infected with Moloney murine sarcoma virus (MSV). They were treated twice daily for 5 days after infection. Oral treatment with bis(POM)-
PMEA
at a dose equivalent to 100 or 50 mg of
PMEA
per kg of body weight per day proved markedly effective in delaying MSV-induced tumor formation and death of the mice. Oral bis(POM)-
PMEA
afforded anti-MSV efficacy equal to that of subcutaneous
PMEA
given at equimolar doses. Oral treatment with
PMEA
or diphenyl-
PMEA
proved less efficient. Similarly, in mice infected with Friend leukemia virus (FLV), oral treatment with bis(POM)-
PMEA
at a dose equivalent to 100 or 50 mg of
PMEA
per kg per day effected a marked inhibition of FLV-induced
splenomegaly
(87 and 48% inhibition, respectively), the efficacy being equal to that of
PMEA
given subcutaneously at equivalent doses. Pharmacokinetic experiments with mice showed that the oral bioavailabilities of
PMEA
following oral gavage of bis(POM)-
PMEA
, diphenyl-
PMEA
, or
PMEA
(at a dose equivalent to 50 mg of
PMEA
per kg) were 53,3, and 16%, respectively. These data were calculated from the levels of free
PMEA
in plasma. Also, the recoveries of free
PMEA
in the urine upon oral administration of bis(POM)-
PMEA
, diphenyl-
PMEA
, or
PMEA
(at a dose equivalent to 25 mg of
PMEA
per kg) were 48, 4, and 7%, respectively. Oral bis(POM)-
PMEA
was not recovered from plasma, suggesting that it was readily cleaved to free
PMEA
. In contrast, diphenyl-
PMEA
was not efficiently cleaved to free
PMEA
, resulting in a rather low oral bioavailability of
PMEA
from this prodrug. Bis(POM)-
PMEA
appears to be an efficient oral prodrug of
PMEA
that deserves further clinical evaluation in human immunodeficiency virus-infected individuals.
...
PMID:Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine. 878 73
Antiarthritic effects of two acyclic nucleoside phosphonates, 9-(2-phosphonomethoxyethyl)adenine (
PMEA
;
Adefovir
) and 9-(2-phosphonomethoxypropyl)adenine (PMPA), as well as their more bioavailable prodrugs, bis(pivaloyloxymethyl)ester of
PMEA
[bis(POM)-
PMEA
;
Adefovir Dipivoxil
] and bis(isopropyloxycarbonyloxymethyl)ester of PMPA [bis(POC)-PMPA], were investigated in a model of adjuvant-induced arthritis in Lewis rats. The drugs were injected subcutaneously at doses of 5-50 mg/kg.
PMEA
and its prodrug inhibited by > 80% arthritic paw swelling,
splenomegaly
and fibroadhesive perisplenitis. Both prophylactic and therapeutic dosing regimens were effective. Neither PMPA nor bis(POC)-PMPA suppressed development of arthritic lesions. Substantially reduced nitrite + nitrate levels were detected in serum and urine of
PMEA
-treated animals as compared to those of untreated diseased controls. Also, complete suppression of the disease-associated, greatly enhanced systemic levels of the chemokine, RANTES (regulated upon activation, normal T cell expressed and secreted), was observed in rats injected with
PMEA
. Additional in vitro studies showed that
PMEA
does not change, PMPA enhances, and both prodrugs inhibit the immune-activated NO production. Under the same conditions
PMEA
inhibits, while PMPA slightly stimulates, secretion of RANTES. Collectively, these data suggest that the in vivo-inhibited production of nitric oxide (NO) is a consequence rather than a mechanism of antiarthritic action of
PMEA
. Possible mechanisms for the anti-RANTES activity of
PMEA
remains to be firmly established.
...
PMID:Chemokines, nitric oxide and antiarthritic effects of 9-(2-phosphonomethoxyethyl)adenine (Adefovir). 1044 94
Aleutian disease virus (
ADV
, Amdovirus, Parvoviridae) primarily infects farmed mustelids (mink and ferrets) but also other fur-bearing animals and humans. Three Aleutian disease (AD) cases have been described in captive striped skunks; however, little is known about the relevance of AD in free-ranging carnivores. This work describes the pathological findings and temporospatial distribution in 7 cases of AD in free-ranging striped skunks. All cases showed neurologic disease and were found in a 46-month period (2010-2013) within a localized geographical region in California. Lesions included multisystemic plasmacytic and lymphocytic inflammation (ie, interstitial nephritis, myocarditis, hepatitis, meningoencephalitis, pneumonia, and splenitis), glomerulonephritis, arteritis with or without fibrinoid necrosis in several organs (ie, kidney, heart, brain, and spleen),
splenomegaly
, ascites/hydrothorax, and/or encephalomalacia with cerebral microangiopathy.
ADV
infection was confirmed in all cases by specific polymerase chain reaction and/or in situ hybridization. The results suggest that AD is an emerging disease in free-ranging striped skunks in California.
...
PMID:Aleutian Disease: An Emerging Disease in Free-Ranging Striped Skunks (Mephitis mephitis) From California. 2544 22